skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8123

Rimonabant: the evidence for its use in the treatment of obesity and the metabolic syndrome

Original Research

(1661) Views  (453) Full article downloads

Authors: Mark Waterlow, Paul Chrisp

Published Date February 2008 Volume 2007:2(3) Pages 0 - 0
DOI: http://dx.doi.org/10.2147/CE.S7428

Mark Waterlow, Paul Chrisp

Core Medical Publishing, Knutsford, UK

Introduction: Obesity and overweight affect over 1 billion people worldwide and are leading causes of morbidity and mortality. Clinical features of obesity converge with those of the metabolic syndrome and type 2 diabetes, greatly increasing the risk of long-term adverse outcomes.

Aims: To review the evidence on rimonabant, a novel CB1 receptor antagonist, for the treatment of obese and overweight patients.

Evidence review: There is clear evidence that rimonabant 20 mg/day in conjunction with a hypocaloric diet causes a mean weight loss of 4.6 kg in obese and overweight patients after 1 year’s treatment, with approximately 50% of patients achieving a weight loss of ≥5%. One study demonstrated that weight loss is maintained for up to 2 years. The drug also improves lipid and glycemic cardiovascular risk factors, including high-density lipoprotein cholesterol and insulin resistance, and reduces waist circumference, thus reducing the prevalence of metabolic syndrome. Treatment of obese and overweight diabetic patients with rimonabant decreases glycosylated hemoglobin (HbA1c), including patients previously untreated for diabetes. The effect of rimonabant appears to be partly independent of weight loss. Rimonabant 20 mg/day is generally well tolerated, with mild to moderate transient adverse effects including nausea, diarrhea, dizziness, and anxiety. Approximately 14% of patients receiving rimonabant 20 mg/day discontinued due to adverse effects, primarily depressed mood, although overall rates of depression did not differ significantly compared with placebo.

Place in therapy: The evidence supports the use of rimonabant 20 mg/day along with dietary modification to reduce cardiovascular risk factors in obese and overweight patients, including those with diabetes. The drug is contraindicated in patients receiving antidepressants. Long-term data on cardiovascular outcomes, morbidity, and mortality are eagerly awaited.

Key words: metabolic syndrome, obesity, rimonabant, type 2 diabetes






 

Other articles by Dr Core Journal

Aliskiren in hypertension: evidence for its potential therapeutic value
Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting
Aripiprazole: the evidence of its therapeutic impact in schizophrenia
Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer
Bortezomib: the evidence of its clinical impact in multiple myeloma
Ciclesonide in persistent asthma: the evidence of its therapeutic value
Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia
Donepezil in Alzheimer’s disease: an evidence-based review of its impact on clinical and economic outcomes
Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hyperplasia
Eltrombopag: the emerging evidence of its therapeutic value in thrombocytopenia
Eplerenone: the evidence for its place in the treatment of heart failure after myocardial infarction
Etanercept in psoriasis: the evidence of its therapeutic impact
Exubera® (inhaled insulin): an evidence-based review of its effectiveness in the management of diabetes
Fosphenytoin for the treatment of status epilepticus: an evidence-based assessment of its clinical and economic outcomes
FTY720 in multiple sclerosis: the emerging evidence of its therapeutic value
K-111: the emerging evidence for its potential in the treatment of the metabolic syndrome
Lapatinib: the evidence for its therapeutic value in metastatic breast cancer
Lumiracoxib: the evidence of its clinical impact on the treatment of osteoarthritis
Maraviroc: the evidence for its potential in the management of HIV
Perindopril: the evidence of its therapeutic impact in hypertension
Pramipexole in restless legs syndrome: an evidence-based review of its effectiveness on clinical outcomes
Sevelamer as a phosphate binder in adult hemodialysis patients: an evidence-based review of its therapeutic value
Tigecycline: an evidence-based review of its antibacterial activity and effectiveness in complicated skin and soft tissue and intraabdominal infections
Topiramate: the evidence for its therapeutic value in the prevention of migraine
Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University